JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

Patients with essential thrombocythemia may carry JAK2 (V617F), an MPL substitution, or a calreticulin gene (CALR) mutation. We studied biologic and clinical features of essential thrombocythemia according to JAK2 or CALR mutation status and in relation to those of polycythemia vera. The mutant alle...

詳細記述

保存先:
書誌詳細
主要な著者: Rumi, Elisa, Pietra, Daniela, Ferretti, Virginia, Klampfl, Thorsten, Harutyunyan, Ashot S., Milosevic, Jelena D., Them, Nicole C. C., Berg, Tiina, Elena, Chiara, Casetti, Ilaria C., Milanesi, Chiara, Sant’Antonio, Emanuela, Bellini, Marta, Fugazza, Elena, Renna, Maria C., Boveri, Emanuela, Astori, Cesare, Pascutto, Cristiana, Kralovics, Robert, Cazzola, Mario
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2014
主題:
Myeloid Neoplasia
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3945864/
https://ncbi.nlm.nih.gov/pubmed/24366362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-11-539098
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料